UBI集團訊息
愛滋病「每日用藥」治療模式，可能因一篇台灣研究而改變
UB-421抗體不僅阻止愛滋病毒感染新細胞，它似乎也調整了受試者的免疫細胞，使他們能更容易地擊退病毒。
UBI集團訊息
-
-
View More 
A vaccine for Alzheimer’s is on the verge of becoming a realityUBI集團訊息A vaccine for Alzheimer’s is on the verge of becoming a reality
Now, a mother and daughter team think they have finally found a solution – a vaccine that could inoculate potential sufferers -
View More 
Is an Alzheimer’s Cure on the Horizon?UBI集團訊息Is an Alzheimer’s Cure on the Horizon?
THE FIELD IS LITTERED WITH FAILURES, UNLESS YOU CONSIDER FAILURES LEARNING.– MEI MEI HU -
View More 
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes PatientsUBI集團訊息United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
Investigational New Drug (IND) approval from the U.S. FDA to conduct a phase 2 clinical trial with UB-621 monoclonal antibody for recurrent genital infection -
View More 
聯生藥治療單純皰疹病毒抗體新藥UB-621獲美國FDA核准 執行臨床2期復發型生殖器皰疹試驗UBI集團訊息聯生藥治療單純皰疹病毒抗體新藥UB-621獲美國FDA核准 執行臨床2期復發型生殖器皰疹試驗
抗皰疹病毒單株抗體藥物UB-621已獲得美國FDA批准在由HSV-2感染所引起之復發型生殖器皰疹患者族群上進行臨床第2期試驗 -
View More 
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infectionUBI集團訊息United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
A Multicenter, Single-Arm, 24-Week Study of UB-421 in Combination with Optimized Background Therapy (OBT) Regimen in Patients with Multi-Drug Resistant (MDR) HIV-1 Infection. -
View More 
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected PatientsUBI集團訊息United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
IND approval from China NMPA to conduct a multi-nation, multi-center phase 3 clinical trial with UB-421 substitution monotherapy -
View More 
聯生藥治療愛滋病抗體新藥UB-421獲中國國家藥品監督管理局 核准多國多中心臨床3期試驗UBI集團訊息聯生藥治療愛滋病抗體新藥UB-421獲中國國家藥品監督管理局 核准多國多中心臨床3期試驗
治療愛滋病單株抗體新藥UB-421規劃在台灣、泰國與中國三個地區執行之多國多中心臨床3期試驗 -
View More 
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption (N Engl J Med 2019; 380:1535-1545)UBI集團訊息Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption (N Engl J Med 2019; 380:1535-1545)
It is possible that monotherapy with UB-421 could induce sustained virologic suppression without induction of resistance in HIV-infected persons -
View More 
Novel antibody may suppress HIV for up to four months (NIH News Releases)UBI集團訊息Novel antibody may suppress HIV for up to four months (NIH News Releases)
NIH researchers, international collaborators report results of small, open-label study -
-
View More 
美國時代雜誌對新英格蘭醫學期刊4月18日週刊發表之聯生藥UB-421突破性愛滋病臨床試驗結果相關報導UBI集團訊息美國時代雜誌對新英格蘭醫學期刊4月18日週刊發表之聯生藥UB-421突破性愛滋病臨床試驗結果相關報導
In a new study published in the NEJM, researchers at Taiwan-based UBP report encouraging results with a single injection that seems to stymie HIV as well as daily pill regimens.
-
-
View More 
我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！ -
View More 
我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力–我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力– -
View More 
我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏
TAG相關標籤
POPULAR熱門文章
